Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer

Subbiah, Vivek; J. Kreitman, Robert; A. Wainberg, Zev; Choi, Y.; H.M. Schellens, Jan; Charles Soria, Jean; Y. Wen, Patrick; Zielinski, Christoph; E. Cabanillas, Maria; Urbanowitz, Gladys; Mookerjee, Bijoyesh; Wang, Dazhe; Rangwala, Fatima; Keam, Bhumsuk

doi:10.1200/jco.2017.73.6785

Public

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

Published in Journal of Clinical Oncology • Oct 26, 2017

Authors:

Vivek Subbiah

Robert J. Kreitman

Zev A. Wainberg

Abstract

Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E-mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. Me...

Subject

Trametinib

Anaplastic thyroid cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!